Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
In recent years, several associations between common chronic human disorders and altered gut microbiome composition and function have been reported. In most of these reports, treatment regimens were not controlled for and conclusions could thus be confounded by the effects of various drugs on the microbiota, which may obscure microbial causes, protective factors or diagnostically relevant signals. Our study addresses disease and drug signatures in the human gut microbiome of type 2 diabetes mellitus (T2D). Two previous quantitative gut metagenomics studies of T2D patients that were unstratified for treatment yielded divergent conclusions regarding its associated gut microbial dysbiosis. Here we show, using 784 available human gut metagenomes, how antidiabetic medication confounds these results, and analyse in detail the effects of the most widely used antidiabetic drug metformin. We provide support for microbial mediation of the therapeutic effects of metformin through short-chain fatty acid production, as well as for potential microbiota-mediated mechanisms behind known intestinal adverse effects in the form of a relative increase in abundance of Escherichia species. Controlling for metformin treatment, we report a unified signature of gut microbiome shifts in T2D with a depletion of butyrate-producing taxa. These in turn cause functional microbiome shifts, in part alleviated by metformin-induced changes. Overall, the present study emphasizes the need to disentangle gut microbiota signatures of specific human diseases from those of medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patient treatment with the drug metformin, a variable that subjects had not been stratified for previously, constituted the main determinant of microbial signatures in diabetic cohorts [62].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [62]
In the citing paper
“This action is an important determinant for the anti-hyperglycemic therapeutic effects, the gastrointestinal side effects and possibly the anti-aging effects of metformin (88, 89).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [88]
In the citing paper
“As for C. elegans, metformin use in humans will change the microbiome.”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [88]
In the citing paper
“Studies comparing individuals with T2D treated or not with metformin identified a higher level of E. coli and a lower level of Intestinibacter in the metformin-treated individuals, while confirming reduced levels of butyrate-producing bacteria such as Roseburia spp., F. prausnitzii, and unnamed Clostridiales in the untreated individuals compared to healthy controls5, 6, 34, 35.”
From The gut microbiome in atherosclerotic cardiovascular disease (2017) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
FLASH: fast length adjustment of short reads to improve genome assemblies
Magoč, T., & Salzberg, S. L. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr507 · Cited by 15,366
UCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
A new method for non-parametric multivariate analysis of variance
Anderson, M. J. (2001) · Austral Ecology · doi:10.1111/j.1442-9993.2001.01070.pp.x · Cited by 13,828
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
VEGAN, a package of R functions for community ecology
Dixon, P. (2003) · Journal of Vegetation Science · doi:10.1111/j.1654-1103.2003.tb02228.x · Cited by 6,824
Cited by
Items 201–300 of 1,006
Birkeland, E., Gharagozlian, S., Birkeland, K. I., Valeur, J., Måge, I., Rud, I., & Aas, A.-M. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02282-5 · Cited by 225
Tian, B., Zhao, J., Zhang, M., Chen, Z., Ma, Q., Liu, H., Nie, C., Zhang, Z., An, W., & Li, J. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000745 · Cited by 226
Self-citationIntestinal microbiome and fitness in kidney disease
Meijers, B., Evenepoel, P., & Anders, H.-J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0172-1 · Cited by 224
Homeostasis and dysbiosis of the gut microbiome in health and disease
Das, B., & Nair, G. B. (2019) · Journal of Biosciences · doi:10.1007/s12038-019-9926-y · Cited by 222
From correlation to causality: the case of Subdoligranulum
Van Hul, M., Le Roy, T., Prifti, E., Dao, M. C., Paquot, A., Zucker, J.-D., Delzenne, N. M., Muccioli, G. G., Clément, K., & Cani, P. D. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1849998 · Cited by 219
Self-citationThe promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Mueller, N. T., Differding, M. K., Zhang, M., Maruthur, N. M., Juraschek, S. P., Miller, E. R., Appel, L. J., & Yeh, H.-C. (2021) · Diabetes Care · doi:10.2337/dc20-2257 · Cited by 215
(2020) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2020.04.003 · Cited by 212
Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism
Caparrós-Martín, J. A., Lareu, R. R., Ramsay, J. P., Peplies, J., Reen, F. J., Headlam, H. A., Ward, N. C., Croft, K. D., Newsholme, P., Hughes, J. D., et al. (2017) · Microbiome · doi:10.1186/s40168-017-0312-4 · Cited by 212
Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients
Ticinesi, A., Milani, C., Lauretani, F., Nouvenne, A., Mancabelli, L., Lugli, G. A., Turroni, F., Duranti, S., Mangifesta, M., Viappiani, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10734-y · Cited by 211
Pharmacomicrobiomics: a novel route towards personalized medicine?
Doestzada, M., Vila, A. V., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., Kuipers, F., Wijmenga, C., & Fu, J. (2018) · Protein & Cell · doi:10.1007/s13238-018-0547-2 · Cited by 210
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
Impact of Gut Microbiota on Host Glycemic Control
Gérard, C., & Vidal, H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00029 · Cited by 209
Xu, J., Liang, R., Zhang, W., Tian, K., Li, J., Chen, X., Yu, T., & Chen, Q. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.12986 · Cited by 209
Self-citationZhang, S., Zhao, J., Xie, F., He, H., Johnston, L. J., Dai, X., Wu, C., & Ma, X. (2021) · Obesity Reviews · doi:10.1111/obr.13316 · Cited by 209
Wernimont, S. M., Radosevich, J., Jackson, M. I., Ephraim, E., Badri, D. V., MacLeay, J. M., Jewell, D. E., & Suchodolski, J. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01266 · Cited by 207
Interactive relationships between intestinal flora and bile acids
Guo, X., Okpara, E. S., Hu, W., Yan, C., Wang, Y., Liang, Q., Chiang, J. Y. L., & Han, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158343 · Cited by 206
Gut Microbiota and Type 1 Diabetes
Han, H., Li, Y., Fang, J., Liu, G., Yin, J., Li, T., & Yin, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040995 · Cited by 206
Pan, L., Han, P., Ma, S., Peng, R., Wang, C., Kong, W., Cong, L., Fu, J., Zhang, Z., Yu, H., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.007 · Cited by 206
Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder
Nguyen, T. T., Kosciolek, T., Eyler, L. T., Knight, R., & Jeste, D. V. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.01.013 · Cited by 205
“Based on what is known from other diseases (Forslund et al., 2015; Walters et al., 2014), technical differences (e.g., DNA extraction methods, PCR primers, sequencing platforms, taxonomy databases) can produce systematic biases that can obscure biologically meaningful compositional differences…”
Gut-associated IgA+ immune cells regulate obesity-related insulin resistance
Luck, H., Khan, S., Kim, J. H., Copeland, J. K., Revelo, X. S., Tsai, S., Chakraborty, M., Cheng, K., Tao Chan, Y., Nøhr, M. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11370-y · Cited by 205
Zhong, H., Ren, H., Lu, Y., Fang, C., Hou, G., Yang, Z., Chen, B., Yang, F., Zhao, Y., Shi, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.048 · Cited by 204
Self-citationSun, L., Pang, Y., Wang, X., Wu, Q., Liu, H., Liu, B., Liu, G., Ye, M., Kong, W., & Jiang, C. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.02.004 · Cited by 204
Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice
Lee, H., Lee, Y., Kim, J., An, J., Lee, S., Kong, H., Song, Y., Lee, C.-K., & Kim, K. (2018) · Gut Microbes · doi:10.1080/19490976.2017.1405209 · Cited by 203
“metabolism and SCFA production caused by the gut microbiota.(20,21) As its effect on the gut microbiota contributes to the antidiabetic effect of metformin, we evaluated the characteristics of the gut microbiota in patients treated with metformin with the aim of identifying new therapeutic targets for T2D.”
Bana, B., & Cabreiro, F. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-112618-043650 · Cited by 203
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions
Vernieri, C., Casola, S., Foiani, M., Pietrantonio, F., de Braud, F., & Longo, V. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0615 · Cited by 202
“Finally, the recently described effect of metformin on gut microbiota composition deserves further investigation in light of the potentially significant contribution of intestinal bacteria to systemic metabolism and efficacy of anticancer therapies (140).”
Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?
Hanssen, N. M. J., de Vos, W. M., & Nieuwdorp, M. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.05.005 · Cited by 202
Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications
Zhang, L., Chu, J., Hao, W., Zhang, J., Li, H., Yang, C., Yang, J., Chen, X., & Wang, H. (2021) · Mediators of Inflammation · doi:10.1155/2021/5110276 · Cited by 201
Maifeld, A., Bartolomaeus, H., Löber, U., Avery, E. G., Steckhan, N., Markó, L., Wilck, N., Hamad, I., Šušnjar, U., Mähler, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22097-0 · Cited by 201
Bryrup, T., Thomsen, C. W., Kern, T., Allin, K. H., Brandslund, I., Jørgensen, N. R., Vestergaard, H., Hansen, T., Hansen, T. H., Pedersen, O., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4848-7 · Cited by 200
Self-citationImplication of gut microbiota metabolites in cardiovascular and metabolic diseases
Brial, F., Le Lay, A., Dumas, M.-E., & Gauguier, D. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2901-1 · Cited by 198
Suzuki, H., Hasegawa, S., Fushimi, S., Tagami, K., Nishikawa, M., Kondo, Y., & Yasuda, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-93647-5 · Cited by 196
Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2024) · mBio · doi:10.1128/mbio.02032-23 · Cited by 150
The double burden of diabetes and global infection in low and middle-income countries
Dunachie, S., & Chamnan, P. (2019) · Transactions of The Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/try124 · Cited by 194
Metformin and Autoimmunity: A “New Deal” of an Old Drug
Ursini, F., Russo, E., Pellino, G., D’Angelo, S., Chiaravalloti, A., De Sarro, G., Manfredini, R., & De Giorgio, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01236 · Cited by 194
Jia, J., Dou, P., Gao, M., Kong, X., Li, C., Liu, Z., & Huang, T. (2019) · Diabetes · doi:10.2337/db19-0153 · Cited by 194
The influence of proton pump inhibitors and other commonly used medication on the gut microbiota
Imhann, F., Vich Vila, A., Bonder, M. J., Lopez Manosalva, A. G., Koonen, D. P. Y., Fu, J., Wijmenga, C., Zhernakova, A., & Weersma, R. K. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1284732 · Cited by 192
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J.-J., Dhakal, S., Franconi, F., Gouni-Berthold, I., Heiman, M. L., Kautzky-Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 192
Microbiota and Lifestyle: A Special Focus on Diet
Redondo-Useros, N., Nova, E., González-Zancada, N., Díaz, L. E., Gómez-Martínez, S., & Marcos, A. (2020) · Nutrients · doi:10.3390/nu12061776 · Cited by 189
Causality of small and large intestinal microbiota in weight regulation and insulin resistance
Scheithauer, T. P. M., Dallinga-Thie, G. M., de Vos, W. M., Nieuwdorp, M., & van Raalte, D. H. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.002 · Cited by 188
An online atlas of human plasma metabolite signatures of gut microbiome composition
Dekkers, K. F., Sayols-Baixeras, S., Baldanzi, G., Nowak, C., Hammar, U., Nguyen, D., Varotsis, G., Brunkwall, L., Nielsen, N., Eklund, A. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33050-0 · Cited by 187
Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders
Rastelli, M., Knauf, C., & Cani, P. D. (2018) · Obesity · doi:10.1002/oby.22175 · Cited by 187
Balakumar, M., Prabhu, D., Sathishkumar, C., Prabu, P., Rokana, N., Kumar, R., Raghavan, S., Soundarajan, A., Grover, S., Batish, V. K., et al. (2018) · European Journal of Nutrition · doi:10.1007/s00394-016-1317-7 · Cited by 187
Microbiota and Neurological Disorders: A Gut Feeling
Moos, W. H., Faller, D. V., Harpp, D. N., Kanara, I., Pernokas, J., Powers, W. R., & Steliou, K. (2016) · BioResearch Open Access · doi:10.1089/biores.2016.0010 · Cited by 149
Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis
He, Y., Wu, W., Wu, S., Zheng, H.-M., Li, P., Sheng, H.-F., Chen, M.-X., Chen, Z.-H., Ji, G.-Y., Zheng, Z.-D.-X., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0557-6 · Cited by 185
Self-citationFood additives, contaminants and other minor components: effects on human gut microbiota—a review
Roca-Saavedra, P., Mendez-Vilabrille, V., Miranda, J. M., Nebot, C., Cardelle-Cobas, A., Franco, C. M., & Cepeda, A. (2018) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-017-0564-2 · Cited by 185
Zeng, X., Gao, X., Peng, Y., Wu, Q., Zhu, J., Tan, C., Xia, G., You, C., Xu, R., Pan, S., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00004 · Cited by 185
Gut microbiota and diabetes: From correlation to causality and mechanism
Li, W.-Z., Stirling, K., Yang, J.-J., & Zhang, L. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i7.293 · Cited by 185
Zhang, X., Fang, Z., Zhang, C., Xia, H., Jie, Z., Han, X., Chen, Y., & Ji, L. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0226-y · Cited by 184
Tao, S., Li, L., Li, L., Liu, Y., Ren, Q., Shi, M., Liu, J., Jiang, J., Ma, H., Huang, Z., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01316-7 · Cited by 180
Jia, L., Li, D., Feng, N., Shamoon, M., Sun, Z., Ding, L., Zhang, H., Chen, W., Sun, J., & Chen, Y. Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-07335-0 · Cited by 179
Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
Zhang, Q., & Hu, N. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s286430 · Cited by 179
Das, T., Jayasudha, R., Chakravarthy, S., Prashanthi, G. S., Bhargava, A., Tyagi, M., Rani, P. K., Pappuru, R. R., Sharma, S., & Shivaji, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82538-0 · Cited by 179
Medina-Vera, I., Sanchez-Tapia, M., Noriega-López, L., Granados-Portillo, O., Guevara-Cruz, M., Flores-López, A., Avila-Nava, A., Fernández, M. L., Tovar, A. R., & Torres, N. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.004 · Cited by 179
Tiny microbes, enormous impacts: what matters in gut microbiome studies?
Debelius, J., Song, S. J., Vazquez-Baeza, Y., Xu, Z. Z., Gonzalez, A., & Knight, R. (2016) · Genome Biology · doi:10.1186/s13059-016-1086-x · Cited by 147
Nagata, N., Nishijima, S., Miyoshi-Akiyama, T., Kojima, Y., Kimura, M., Aoki, R., Ohsugi, M., Ueki, K., Miki, K., Iwata, E., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.070 · Cited by 178
Fatty acid overproduction by gut commensal microbiota exacerbates obesity
Takeuchi, T., Kameyama, K., Miyauchi, E., Nakanishi, Y., Kanaya, T., Fujii, T., Kato, T., Sasaki, T., Tachibana, N., Negishi, H., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.12.013 · Cited by 178
Microbiota-gut brain axis involvement in neuropsychiatric disorders
Iannone, L. F., Preda, A., Blottière, H. M., Clarke, G., Albani, D., Belcastro, V., Carotenuto, M., Cattaneo, A., Citraro, R., Ferraris, C., et al. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1638763 · Cited by 177
“, [35]; Forslund et al, [36]; Komaroff, [37] 1038 L.”
Postbiotics as potential new therapeutic agents for metabolic disorders management
Bourebaba, Y., Marycz, K., Mularczyk, M., & Bourebaba, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113138 · Cited by 177
The Role of the Gut Microbiota in the Pathogenesis of Diabetes
Bielka, W., Przezak, A., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010480 · Cited by 176
Gut microbiota: A new target for T2DM prevention and treatment
Liu, L., Zhang, J., Cheng, Y., Zhu, M., Xiao, Z., Ruan, G., & Wei, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.958218 · Cited by 176
“—— Lactobacillus Akkermansia SCFAs↓ Inflammation↑ Glucose and energy disorders (39, 40)”
Metformin attenuated sepsis-related liver injury by modulating gut microbiota
Liang, H., Song, H., Zhang, X., Song, G., Wang, Y., Ding, X., Duan, X., Li, L., Sun, T., & Kan, Q. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2045876 · Cited by 176
“Additionally, a report [29] showed that metformin treatment creates a competitive environment for Escherichia coli using other energy sources, thereby inducing the abundance of gut microbiome alters [32].”
BackgroundHe, K.-Y., Lei, X., Wu, D., Zhang, L., Li, J.-Q., Li, Q., Yin, W.-T., Zhao, Z., Liu, H., Xiang, X.-Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2293312 · Cited by 176
Self-citationCurrent Evidence on the Ocular Surface Microbiota and Related Diseases
Petrillo, F., Pignataro, D., Lavano, M. A., Santella, B., Folliero, V., Zannella, C., Astarita, C., Gagliano, C., Franci, G., Avitabile, T., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8071033 · Cited by 175
Gut Microbiota, Endocrine-Disrupting Chemicals, and the Diabetes Epidemic
Velmurugan, G., Ramprasath, T., Mithieux, G., Swaminathan, K., & Ramasamy, S. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.001 · Cited by 176
Considering gut microbiota in treatment of type 2 diabetes mellitus
Adeshirlarijaney, A., & Gewirtz, A. T. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1717719 · Cited by 176
Jian, H., Liu, Y., Wang, X., Dong, X., & Zou, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043900 · Cited by 173
Brial, F., Chilloux, J., Nielsen, T., Vieira‐Silva, S., Falony, G., Andrikopoulos, P., Olanipekun, M. T., Hoyles, L., Djouadi, F., Neves, A. L., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323314 · Cited by 173
Self-citationWei, S., Bahl, M. I., Baunwall, S. M. D., Hvas, C. L., & Licht, T. R. (2021) · Applied and Environmental Microbiology · doi:10.1128/aem.00395-21 · Cited by 172
Lactobacillus casei CCFM419 attenuates type 2 diabetes via a gut microbiota dependent mechanism
Wang, G., Li, X., Zhao, J., Zhang, H., & Chen, W. (2017) · Food & Function · doi:10.1039/c7fo00593h · Cited by 172
Understanding the role of the gut ecosystem in diabetes mellitus
Aw, W., & Fukuda, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12673 · Cited by 172
Sharpton, S. R., Ajmera, V., & Loomba, R. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.065 · Cited by 169
“These results are consistent with studies that have demonstrated microbiome alterations associated with the use of common medications, such as proton pump inhibitors(32) and metformin.(33) Although it remains unknown to what degree each of these factors modulate the microbiomehost interaction in NAFLD, these potential…”
Microbiota y diabetes mellitus tipo 2
Muñoz‐Garach, A., Díaz-Perdigones, C. M., & Tinahones, F. J. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2016.07.008 · Cited by 169
Letchumanan, G., Abdullah, N., Marlini, M., Baharom, N., Lawley, B., Omar, M. R., Mohideen, F. B. S., Addnan, F. H., Fariha, M. M. N., Ismail, Z., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.943427 · Cited by 171
The role of iron in host–microbiota crosstalk and its effects on systemic glucose metabolism
Mayneris‐Perxachs, J., Moreno‐Navarrete, J. M., & Fernández‐Real, J. M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00721-3 · Cited by 170
The Gut Microbiome in Hypertension: Recent Advances and Future Perspectives
Avery, E. G., Bartolomaeus, H., Maifeld, A., Marko, L., Wiig, H., Wilck, N., Rosshart, S. P., Forslund, S. K., & Müller, D. N. (2021) · Circulation Research · doi:10.1161/circresaha.121.318065 · Cited by 168
Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., Dulai, P. S., Caussy, C., Bettencourt, R., Highlander, S. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.002 · Cited by 168
Drug–gut microbiota interactions: implications for neuropharmacology
Walsh, J., Griffin, B. T., Clarke, G., & Hyland, N. P. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14366 · Cited by 149
Zhou, X., Shen, X., Johnson, J. S., Spakowicz, D. J., Agnello, M., Zhou, W., Avina, M., Honkala, A., Chleilat, F., Chen, S. J., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.02.012 · Cited by 167
Bajaj, J. S., Liu, E. J., Kheradman, R., Fagan, A., Heuman, D. M., White, M., Gavis, E. A., Hylemon, P., Sikaroodi, M., & Gillevet, P. M. (2018) · Gut · doi:10.1136/gutjnl-2016-313170 · Cited by 167
Kim, B.-S., Choi, C. W., Shin, H., Jin, S.-P., Bae, J.-S., Han, M., Seo, E. Y., Chun, J., & Chung, J. H. (2019) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1811.11023 · Cited by 149
Riaz Rajoka, M. S., Shi, J., Mehwish, H. M., Zhu, J., Li, Q., Shao, D., Huang, Q., & Yang, H. (2017) · Food Science and Human Wellness · doi:10.1016/j.fshw.2017.07.003 · Cited by 166
Differential Analysis of Hypertension-Associated Intestinal Microbiota
Dan, X., Mushi, Z., Baili, W., Han, L., Enqi, W., Huanhu, Z., & Li, S. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.29322 · Cited by 166
Xu, X., Gao, Z., Yang, F., Yang, Y., Chen, L., Han, L., Zhao, N., Xu, J., Wang, X., Ma, Y., et al. (2020) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.09.007 · Cited by 156
Self-citationHarsch, I. A., & Konturek, P. C. (2018) · Medical Sciences · doi:10.3390/medsci6020032 · Cited by 165
Strain-level epidemiology of microbial communities and the human microbiome
Yan, Y., Nguyen, L. H., Franzosa, E. A., & Huttenhower, C. (2020) · Genome Medicine · doi:10.1186/s13073-020-00765-y · Cited by 166
Deng, Y., Huang, L., Zhang, C., Xie, P., Cheng, J., Wang, X., & Liu, L. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.03.057 · Cited by 164
Zhang, J., Ni, Y., Qian, L., Fang, Q., Zheng, T., Zhang, M., Gao, Q., Zhang, Y., Ni, J., Hou, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202100536 · Cited by 163
Comparison of Fecal Collection Methods for Microbiome and Metabolomics Studies
Wang, Z., Zolnik, C. P., Qiu, Y., Usyk, M., Wang, T., Strickler, H. D., Isasi, C. R., Kaplan, R. C., Kurland, I. J., Qi, Q., et al. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00301 · Cited by 163
The microbiome: An emerging key player in aging and longevity
Kim, M., & Benayoun, B. A. (2020) · Translational Medicine of Aging · doi:10.1016/j.tma.2020.07.004 · Cited by 143
Lee, C. B., Chae, S. U., Jo, S. J., Jerng, U. M., & Bae, S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073566 · Cited by 163
Correcting for batch effects in case-control microbiome studies
Gibbons, S. M., Duvallet, C., & Alm, E. J. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006102 · Cited by 162
Dwiyanto, J., Hussain, M. H., Reidpath, D., Ong, K. S., Qasim, A., Lee, S. W. H., Lee, S. M., Foo, S. C., Chong, C. W., & Rahman, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82311-3 · Cited by 161
The gut microbiome and mental health: implications for anxiety- and trauma-related disorders
Malan-Muller, S., Valles-Colomer, M., Raes, J., Lowry, C. A., Seedat, S., & Hemmings, S. M. J. (2018) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2017.0077 · Cited by 161
Self-citationNew insights into the mechanisms of high‐fat diet mediated gut microbiota in chronic diseases
Chen, J., Xiao, Y., Li, D., Zhang, S., Wu, Y., Zhang, Q., & Bai, W. (2023) · iMeta · doi:10.1002/imt2.69 · Cited by 161
Zhang, H.-Y., Tian, J.-X., Lian, F.-M., Li, M., Liu, W.-K., Zhen, Z., Liao, J.-Q., & Tong, X.-L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110857 · Cited by 161
Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy
Zhang, L., Wang, Z., Zhang, X., Zhao, L., Chu, J., Li, H., Sun, W., Yang, C., Wang, H., Dai, W., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00324-22 · Cited by 161
Armour, C. R., Nayfach, S., Pollard, K. S., & Sharpton, T. J. (2019) · mSystems · doi:10.1128/msystems.00332-18 · Cited by 160
Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?
Aron‐Wisnewsky, J., Clément, K., & Nieuwdorp, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1180-z · Cited by 163
GMrepo: a database of curated and consistently annotated human gut metagenomes
Wu, S., Sun, C., Li, Y., Wang, T., Jia, L., Lai, S., Yang, Y., Luo, P., Dai, D., Yang, Y.-Q., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz764 · Cited by 159
Metadata
- Authors
- MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Krogh Pedersen, H., Arumugam, M., Kristiansen, K., Yvonne Voigt, A., Vestergaard, H., Hercog, R., Igor Costea, P., Roat Kultima, J., Li, J., Jørgensen, T., Levenez, F., Dore, J., Bjørn Nielsen, H., Brunak, S., Raes, J., Hansen, T., Wang, J., Dusko Ehrlich, S., Bork, P., & Pedersen, O.
- Affiliations
- Vrije Universiteit Brussel (BE)
- University of Copenhagen (DK)
- Rega Institute for Medical Research (BE)
- European Molecular Biology Laboratory (DE)
- Microbiologie de l’alimentation au service de la santé (FR)
- BGI Group (China) (CN)
- Corresponding author
- Pedersen, Oluf
- ORCID
- Venue
- Nature
- Published
- 2015-12-02
- Volume
- 528
- Issue
- 7581
- Pages
- 262-266
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4681099
- OpenAlex
- W2188930066
- Cited by
- 2,116
- References
- 49
- Citations by year
- 2026: 113 · 2025: 167 · 2024: 212 · 2023: 194 · 2022: 253 · 2021: 270 · 2020: 256 · 2019: 185 · 2018: 197 · 2017: 150 · 2016: 112 · 2015: 3
- FWCI
- 66.83
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-05-04)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Innovationsfonden
- European Molecular Biology Laboratory
- European Commission (600375, 2007–2013, FP7 2007-2013, HORIZON2020, FP7/2007, 305312, 201052, 261376)
- Agence Nationale de la Recherche (ANR-11-DPBS-0001)
- Lundbeckfonden
- Novo Nordisk
- Göteborgs Universitet
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Novo Nordisk Foundation Center for Basic Metabolic Research
- H. Lundbeck A/S
- FP7 Ideas: European Research Council (268985)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- type 2 diabetes, gut microbiota, metformin, antidiabetic drugs, dysbiosis, confounding by treatment, short-chain fatty acids, butyrate, Escherichia, metagenome-wide association study
- MeSH terms
- Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Metformin, RNA, Ribosomal, 16S, Biodiversity, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.